We are focusing first on Addressing the overlooked need in Von Willebrand disease [VWD]
We are focusing first on Addressing the overlooked need in Von Willebrand disease [VWD]
VWD IS THE MOST COMMON BLOOD DISORDER, BUT IT OFTEN GOES UNSEEN
VWD IS THE MOST COMMON BLOOD DISORDER, BUT IT OFTEN GOES UNSEEN
Patients living with VWD have defective or low amounts of von Willebrand factor (VWF), a protein that facilitates blood clotting. For VWD patients, blood clots either form incorrectly or take longer to develop, leading to heavy bleeding that can cause organ damage and impact quality of life.
Due to low disease awareness and challenges along the diagnostic and treatment journey, VWD in some patients may be undiagnosed or not properly treated.1,2
Patients living with VWD have defective or low amounts of von Willebrand factor (VWF), a protein that facilitates blood clotting. For VWD patients, blood clots either form incorrectly or take longer to develop, leading to heavy bleeding that can cause organ damage and impact quality of life.
Due to low disease awareness and challenges along the diagnostic and treatment journey, VWD in some patients may be undiagnosed or not properly treated.1,2
VMD PATIENTS NAVIGATE MANY CHALLENGES
VMD PATIENTS NAVIGATE MANY CHALLENGES
VWD IMPACTS DAY-TO-DAY LIVING
VWD IMPACTS DAY-TO-DAY LIVING
Bleeding caused by VWD significantly impacts patients’ daily lives. Due to the potential for injury, some patients avoid physical activity. Others miss school or work due to bleeding or treatment that requires frequent IV infusions.3 For women and girls, living with VWD can mean experiencing heavy bleeding during menstruation and childbirth, or facing a 10x higher risk of mortality during childbirth due to bleeding.1,4,5
Bleeding caused by VWD significantly impacts patients’ daily lives. Due to the potential for injury, some patients avoid physical activity. Others miss school or work due to bleeding or treatment that requires frequent IV infusions.3 For women and girls, living with VWD can mean experiencing heavy bleeding during menstruation and childbirth, or facing a 10x higher risk of mortality during childbirth due to bleeding.1,4,5
PATIENTS DIAGNOSED WITH VWD HAVE LIMITED TREATMENT OPTIONS
PATIENTS DIAGNOSED WITH VWD HAVE LIMITED TREATMENT OPTIONS
Current VWD treatment options have significant limitations. They may have minimal effectiveness or be associated with high treatment burden.1,6,7 We are focused on developing better treatments to address the unmet needs of VWD patients.
Current VWD treatment options have significant limitations. They may have minimal effectiveness or be associated with high treatment burden.1,6,7 We are focused on developing better treatments to address the unmet needs of VWD patients.
We believe VWD patients deserve better treatment options that can prevent and manage bleeding, as well as improve quality of life.
We believe VWD patients deserve better treatment options that can prevent and manage bleeding, as well as improve quality of life.
Our first-in-class Protein S modulator, VGA039,
has the potential to improve the lives of people living with VWD.
Our first-in-class Protein S modulator, VGA039, has the potential to improve the lives of people living with VWD.
VGA039: A NOVEL APPROACH TO RESTORING BLOOD CLOTTING IN VWD
VGA039: A NOVEL APPROACH TO RESTORING BLOOD CLOTTING IN VWD
VGA039 is a monoclonal antibody that modulates Protein S, a key component in facilitating proper blood clotting.
Through its targeting of multiple steps in the blood-clotting process and its convenient delivery as a subcutaneous injection, VGA039 has the potential to transform the treatment experience for people living with VWD.
VGA039 is a monoclonal antibody that modulates Protein S, a key component in facilitating proper blood clotting.
Through its targeting of multiple steps in the blood-clotting process and its convenient delivery as a subcutaneous injection, VGA039 has the potential to transform the treatment experience for people living with VWD.
VGA039 TARGETS A FUNDAMENTAL MECHANISM THAT CAN RESTORE PROPER CLOTTING IN VWD
VGA039 TARGETS A FUNDAMENTAL MECHANISM THAT CAN RESTORE PROPER CLOTTING IN VWD
VGA039 WAS SPECIFICALLY DESIGNED TO PROMOTE PLATELET ACTIVATION, PLUG FORMATION, AND CLOT STABILIZATION
VGA039 WAS SPECIFICALLY DESIGNED TO PROMOTE PLATELET ACTIVATION, PLUG FORMATION, AND CLOT STABILIZATION
Expanded Access to Investigational Medicines Prior to Regulatory Approval
At Vega Therapeutics, we aim to provide patients access to our investigational therapies in the most clinically appropriate manner. Vega Therapeutics does not currently accept or grant requests for expanded access to any of our investigational therapies outside of clinical trials.
References: 1. Centers for Disease Control and Prevention. What is Von Willebrand Disease? April 1, 2021. Accessed September 26, 2022. https://www.cdc.gov/ncbddd/